Longeveron (LGVN) AI Stock Analysis

• Market Cap: $17.01M
• Dividend Yield: N/A
• Average Volume (3M): 1.44M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.44
• Revenue Growth: 68.67%
• EPS Growth: 85.44%
• Country: US
• Employees: 25
• Sector: Healthcare
• Sector Strength: 47
• Industry: Biotechnology
• EPS (TTM): -0.33
• Shares Outstanding: 19,312,218
• 10 Day Avg. Volume: 2,631,813
• 30 Day Avg. Volume: 1,439,762
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.61
• Enterprise Value/Revenue: 4.98
• Enterprise Value/Gross Profit: 6.32
• Enterprise Value/Ebitda: -0.55
• 1Y Price Target: $2.67
• Price Target Upside: 225.61% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 44 Neutral
• Price Target: $1.00 ▲(21.95% Upside)

Longeveron's overall stock score is primarily impacted by its financial performance, which shows significant challenges with declining revenues and persistent losses. Technical analysis further indicates bearish momentum. While the earnings call highlighted strategic progress, financial uncertainties and increased expenses weigh heavily on the score.

Positive Factors

Financial Support

Grant funding from the National Institute of Health offsets the expenses of the study, providing financial support for the research.

Partnership Opportunities

Longeveron has gained FDA alignment on an adaptive single P2/3 pivotal trial design for Alzheimer's disease, which should make the program more attractive for partnering with a larger company.

Regulatory Support

The FDA's ongoing commitment to streamlining approvals for rare diseases, particularly rare pediatric diseases, is expected to support the company's filing on a positive note.

Negative Factors

Capital Requirements

Longeveron reported a net loss, and it is expected that the company will require additional capital.

Financial Performance

The company's recent equity financing has led to dilution, which has contributed to a lowered 12-month price target from $6.00 to $4.00.

Regulatory Risks

Risks include the potential failure of Lomecel-B in the ELPIS-II trial of HLHS patients and inability to obtain regulatory approval.

Longeveron Business Overview & Revenue Model

Company Description

Longeveron Inc. is a biotechnology company focused on developing cellular therapies for aging-related and life-threatening conditions. The company is engaged in the research and development of regenerative medicine, specializing in the use of medicinal signaling cells (MSCs) derived from donor bone marrow. Longeveron aims to harness the potential of these cells to address medical conditions associated with aging, such as frailty, and other severe diseases, thereby improving patient outcomes and enhancing quality of life.

How the Company Makes Money

Longeveron primarily generates revenue through its clinical development programs, where it conducts clinical trials to evaluate the efficacy and safety of its proprietary cell therapies. The company may receive funding from government grants, research collaborations, and partnerships with other medical institutions to support its research initiatives. Additionally, Longeveron may earn revenue from licensing agreements if its therapies receive regulatory approval and are commercialized. The company's financial performance is significantly influenced by the progress of its clinical trials, regulatory milestones, and strategic partnerships that facilitate the advancement and potential commercialization of its therapies.

Longeveron Financial Statement Overview

Summary

Longeveron faces significant financial challenges with declining revenues and persistent losses impacting profitability. Despite a high gross profit margin and low leverage, negative cash flows and return on equity highlight ongoing operational and financial difficulties.

Income Statement

Longeveron shows a declining revenue trend with a negative revenue growth rate of -6.83% in the TTM. The company has consistently negative net profit margins, indicating ongoing losses. Gross profit margins are relatively high at 78.77%, but the negative EBIT and EBITDA margins highlight significant operational challenges.

Balance Sheet

The company's debt-to-equity ratio is low at 0.05, indicating minimal leverage, which is a positive aspect. However, the return on equity is significantly negative at -95.90%, reflecting poor profitability relative to shareholder equity. The equity ratio stands at 75.57%, suggesting a strong equity base relative to total assets.

Cash Flow

Longeveron has negative operating cash flow and free cash flow, with a declining free cash flow growth rate of -8.43% in the TTM. The operating cash flow to net income ratio is negative, indicating cash flow challenges. The free cash flow to net income ratio is close to 1, suggesting that cash flow is closely aligned with net income, albeit negative.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.07M	2.39M	709.00K	1.22M	1.31M	5.63M
Gross Profit	1.63M	1.88M	221.00K	497.00K	590.00K	1.83M
EBITDA	-18.61M	-15.56M	-20.06M	-17.15M	-16.18M	-2.93M
Net Income	-18.54M	-15.97M	-21.41M	-18.84M	-17.05M	-3.72M
Balance Sheet
Total Assets	16.75M	25.56M	12.08M	27.41M	42.77M	9.24M
Cash, Cash Equivalents and Short-Term Investments	10.33M	19.23M	5.36M	19.66M	35.04M	815.80K
Total Debt	639.00K	1.45M	2.04M	2.60M	3.14M	4.14M
Total Liabilities	4.09M	3.67M	5.34M	6.91M	5.31M	7.28M
Stockholders Equity	12.66M	21.89M	6.74M	20.50M	37.45M	1.96M
Cash Flow
Free Cash Flow	-14.27M	-14.86M	-19.70M	-14.82M	-10.95M	-2.63M
Operating Cash Flow	-14.51M	-13.87M	-19.00M	-13.97M	-9.64M	-2.36M
Investing Cash Flow	-1.01M	-640.00K	8.19M	-677.00K	-10.70M	-261.50K
Financing Cash Flow	13.48M	28.79M	5.26M	-509.00K	45.17M	1.58M

Longeveron Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.82
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LGVN, the sentiment is Negative. The current price of 0.82 is below the 20-day moving average (MA) of 1.01, below the 50-day MA of 1.27, and below the 200-day MA of 1.54, indicating a bearish trend. The MACD of -0.17 indicates Negative momentum. The RSI at 35.59 is Neutral, neither overbought nor oversold. The STOCH value of 55.98 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LGVN.

Longeveron Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
OVID	54 Neutral	$86.75M	―	-52.77%	―	1071.91%	-27.61%
Sector *	51 Neutral	$7.83B	-0.18	-40.10%	2.29%	21.46%	-2.03%
LGVN	44 Neutral	$17.01M	―	-134.50%	―	68.67%	85.44%
PASG	44 Neutral	$21.97M	―	-88.27%	―	―	32.57%
NNVC	42 Neutral	$22.98M	―	-99.84%	―	―	13.83%
CALC	39 Underperform	$40.10M	―	-209.36%	―	―	15.19%
CMMB	33 Underperform	$70.35M	―	-120.76%	―	―	47.86%

Longeveron Corporate Events

Longeveron Closes $5 Million Public Stock Offering

On August 8, 2025, Longeveron announced the pricing of a public offering of its Class A common stock, which closed on August 11, 2025. The offering, managed by H.C. Wainwright & Co., is expected to generate approximately $5 million upfront, with an additional potential $12.5 million from short-term warrants. The proceeds will support the development of laromestrocel for various conditions and regulatory activities.

Longeveron Gains FDA Approval for Laromestrocel Trial

On July 8, 2025, Longeveron Inc. announced that the U.S. FDA has approved their Investigational New Drug application for laromestrocel, allowing the company to initiate a Phase 2 pivotal registration clinical trial for treating pediatric dilated cardiomyopathy (DCM). This approval marks a significant milestone in pediatric cardiovascular treatment, as current options are limited and often result in heart transplants or death for nearly 40% of affected children. The trial is expected to begin in the first half of 2026, and laromestrocel’s potential to repair damaged heart tissue could be groundbreaking for pediatric cardiovascular diseases.

Longeveron Elects New Director at Annual Meeting

On June 13, 2025, Longeveron held its annual stockholders’ meeting where three key proposals were voted on. The stockholders elected Rock Soffer as a Class I director for a three-year term, approved an amendment to the 2021 Incentive Award Plan to increase authorized shares, and ratified CBIZ CPAs P.C. as the independent registered public accounting firm for fiscal 2025.